Company intelligence / Profile preview
POLYVAC
Vietnampolyvac.com.vn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
POLYVAC has successfully produced MR (Measles-Rubella) vaccine that was incorporated into Vietnam's Expanded Program on Immunization in March 2018.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesBiologicals
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo Biotech Co., Ltd. (formerly Kitasato Daiichi Sankyo Vaccine)Japan International Cooperation Agency (JICA)
Beyond the preview
Go deeper on POLYVAC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLYVAC.